Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677465 | 0.96 | TSHR (0.52) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL2677457 | 0.95 | HPGD (0.53) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL3595898 | 0.94 | TSHR (0.52) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL18415359 | 0.91 | HPGD (0.68) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL1911828 | 0.89 | HPGD (0.72) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL2678757 | 0.86 | CNR2 (0.49) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL26124277 | 0.83 | HPGD (0.68) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL2677613 | 0.81 | ALDH1A1 (0.72) | HPGDTSHRALDH1A1CNR2HTT | |
| SCHEMBL27752273 | 0.81 | HPGD (0.72) | HPGDTSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3828585 | 0.81 | ALDH1A1 (0.78) | HPGDTSHRALDH1A1CNR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HPGD 422/4885TSHR 995/4885ALDH1A1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.